Data-Driven Investment Insights
Welcome to TICKR-BIO
Your Edge in the Market
Why TICKR-BIO
Sample Data
| Company | Previous Day Close Price | Drug & Indication | Phase | Catalyst Date | Catalyst Description |
|---|---|---|---|---|---|
| JSPR Jasper Therapeutics | $21.57 | Briquilimab CD117 Binder (Antibody) in Chronic Spontaneous Urticaria | P1 | 2025-01-06 | Jasper Therapeutics reported positive initial data on Briquilimab in mast cell-driven diseases, achieving over 90% clinical response in patients with no serious adverse events. Presentation on upcoming Beacon study data expected January 6, 2025. |
| VRTX Vertex | $397.27 | Vanzacaftor CFTR Modulator (Small Molecule) in Acute Pain|Pain Unspecified | Approval | 2025-01-02 | PDUFA target action dates for Vanzacaftor triple in CF and Suzetrigine in acute pain are January 2 and January 30, 2025. |
| RYTM Rhythm | $56.12 | Setmelanotide MCR Agonist (Peptide/Protein) in Bardet-Biedl Syndrome | Approval | 2024-12-26 | PDUFA goal date: December 26, 2024, for new application of imcivree to treat rare genetic obesity disorders in children. |
| SNDX Syndax | $13.08 | Revumenib MEN1 Inhibitor (Small Molecule) in Acute Leukemia|Leukemia | Approval | 2024-12-26 | PDUFA action date for Revumenib in r/r kmt2ar acute leukemia is December 26, 2024. |
Types of Catalysts
Clinical Outcomes
Clinical outcomes announcements from pharmaceutical companies are crucial events with broad implications for healthcare providers, patients, investors, regulatory bodies, and the companies themselves. These announcements reveal the efficacy, safety, and market potential of new drugs or treatments in clinical trials. Recognizing the significance of these announcements is essential due to their impact on medical practice, financial markets, regulatory processes, and investment strategies.
Drug Approvals Dates
Get ahead of investment opportunities with our proprietary database of upcoming FDA approvals, which provide timely insights on products about to hit the market.
Established under the Prescription Drug User Fee Act of 1992, PDUFA dates represent deadlines by which the FDA commits to review and make decisions on New Drug Applications (NDAs) and Biologics License Applications (BLAs). Understanding PDUFA dates is essential for stakeholders in the pharmaceutical and biotechnology industries, as they significantly impact drug development, commercialization timelines, and investment strategies.
Pricing
Free
- Access all updates for catalyst events and dates over the next 14 days, along with phases and indications Catalyst description
- Basic information regarding products tied to catalyst movement
Silver
- Access all updates for catalyst events and dates over the next 14 days, including the proprietary data below:
- Catalyst description
- Key product information related to targets and modality
- Market mover designation based on our proprietary model
- Critical asset metric denoting the importance of an asset to the company
- Novel status of drug and target
- Limited access to PRYZM biopharma product database
Gold
- Access all updates for catalyst events and dates – along with clinical trial phases and indications – over the next 30 days, including the proprietary data below:
- Catalyst description
- Key product information related to targets and modality
- Market mover designation based on our proprietary model
- Critical asset metric denoting the importance of an asset to the company
- Novel status of drug and target
- Limited access to PRYZM biopharma product database
About Us
Powered by OZMOSI
TICKR-BIO provides access to alternative data for making informed investment decisions. Founded by OZMOSI, a leading healthcare data company, we offer data, insights, and tools for informed healthcare investment decisions at every level. Our mission is to equip investors with the knowledge and data they need to make smarter, more profitable choices.
